Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Obstet Gynaecol India ; 72(5): 454-457, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-36458059

RESUMEN

Global incidence of non-Hodgkin's lymphoma (NHL) is 3% of which 1% occurs in extranodal lymphoma. Plasmablastic lymphoma (PBL) is a rare and aggressive variant of diffuse large B-cell lymphoma (DLBCL). It is usually seen in human immunodeficiency virus (HIV) infected patients. PBL occurring in extranodal site, particularly female genital tract, is very rare, and only few case reports have been reported. Here, we report a unique rare case of uterine PBL in an HIV/Epstein-Barr virus-negative patient that was initially diagnosed as endometrioid carcinoma.

2.
Indian J Otolaryngol Head Neck Surg ; 74(Suppl 3): 6241-6245, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36742567

RESUMEN

Arteriovenous malformations (AVMs) are most commonly reported in the brain whereas in head and neck region they are rare i.e. incidence is 0.1% of the general population. Commonly managed by surgical excision, embolization, sclerotherapy. Here we present a case of 18-year-old female with AV malformation within buccinator muscle which was recurrent and was treated with compartmentalization followed by sclerotherapy and surgical excision.

5.
Indian J Surg Oncol ; 9(2): 157-161, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29887693

RESUMEN

Nearly half of newly diagnosed cases of bladder cancer are low grade, noninvasive, and papillary tumors. The standard treatment for non-muscle-invasive bladder cancer (NMIBC) has been transurethral resection of the bladder tumor (TUR-BT) with or without adjuvant intravesical instillation (IVI) of chemotherapy or Bacillus Calmette-Guerin (BCG) therapy. NMIBC is known to be associated with high rates of recurrence and risk of progression. In this study, we have retrospectively analyzed the clinical outcome of initially diagnosed multiple low-grade Ta tumors, with a special focus on tumor recurrence and worsening progression (WP) pattern. We retrospectively reviewed 42 patients with primary, multiple, low-grade Ta bladder cancer. We defined WP as confirmed high-grade Ta, all T1 or Tis/concomitant CIS of bladder recurrence, upper urinary tract recurrence (UTR), or progression to equal to or more than T2. The associations between clinico-pathological factors and tumor recurrence as well as WP pattern were analyzed. Tumor recurrence and WP occurred in 23 (54.76%) and 8 (19.04%) patients during follow-up (median follow-up: 57.38 months), respectively. WP to high grade/stage was seen in 8 patients. Multivariate analysis demonstrated that use of tobacco (p < 0.0001) and absence of IVI (p < 0.0001) were significant risk factors for tumor recurrence. The 5-year recurrence-free survival rate for non-tobacco users (74.0%) was significantly higher than that for tobacco users (42.5%, p = 0.0001), and also higher for patients receiving intravesical instillation (84.2 vs. 30.0% without IVI, p = 0.0001). Recurrence is common in patients with low-grade, Ta bladder cancer, especially in the setting of multiplicity. Recurrences occurred in 54.76% of patients and WP occurred in 19.04% of patients. Use of tobacco and non-use of IVI were strongly associated with high recurrence rate.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA